List of eTables and eFigures

eTables:

eTable 1. Diagnostic codes for complications.

eTable 2. Form of all covariates.

eTable 3. Mixed-effects regression model examining the adjusted association between anesthetic type and 30-day mortality among the 20,988 study patients.

eTable 4. Characteristics of the propensity score-matched cohorts.

eTable 5. Characteristics of the 13,176 study patients \geq 65-years old with outpatient prescription drug data stratified by anesthetic technique.

eTable 6. Mixed-effects regression model examining the adjusted association between anesthetic type and 30-day mortality among the 13,176 patients \geq 65-years old with outpatient prescription drug data.

eTable 7. Incidence of secondary outcomes and results of mixed-effects regression models examining differences in these outcomes between groups.

eFigures:

eFigure 1. Loess smoothed plot of the percentage of neuraxial anesthesia, anticoagulant, and antiplatelet use across the study period. Shaded areas around the plotted line represent 95% confidence intervals.

Outcome	Description	Codes
In-hospital coronary revascularization	Revascularization (within index DAD record)	CCI code IJ50 or 1IJ57GQ)
In hospital acute kidney injury	Acute Kidney Injury (within index DAD record)	N17 with Diagnosis type=2
In hospital myocardial infarction	Major adverse cardiac event (within index DAD record)	I21, I22, I20, I23.82, I24 with Diagnosis type=2
In hospital ventricular arrhythmia	New cardiac ventricular arrhythmia (within index DAD)	I490, with Diagnosis type=2
In hospital heart failure	New heart failure (within index DAD)	I50, with Diagnosis type=2
In hospital ischemic stroke	New stroke (within index DAD)	I63, I64 with Diagnosis type=2
In hospital hemorrhagic stroke	New stroke (within index DAD)	I60, I61, I62 with Diagnosis type=2
In hospital transient ischemic attack	New transient ischemic attack (within index DAD)	G45 with Diagnosis type=2
In hospital pneumonia	New pneumonia (within index DAD)	J12, J13, J14, J15, J16, J17, J18, P23 with Diagnosis type=2
In hospital pulmonary embolism	New pulmonary embolus (within index DAD)	I26 with Diagnosis type=2

eTable 1. Diagnostic Codes for Complications.

In hospital deep vein thrombosis	new deep vein thrombosis (within index DAD)	DXCODE (i) = I801; I802; I808; I822; I823; I828; I829 with Diagnosis type=2
DAD: discharge abstract database		

eTable 2. Form of all Covariates.

Covariate	Form
Neuraxial instead of general anesthesia	Binary
Demographics and hospital surgical volume	
Age	Restricted cubic spline with 5 knots
Female	Binary
Urban instead of rural residence	Binary
Long-term care facility resident	Binary
Income quintile	5-level categorical
Smoking cessation consultation in the year before surgery	Binary
Hospital lower limb revascularization surgery volume	Restricted cubic spline with 5 knots
Hospital-patient One-Year Mortality Risk score (per-point	Continuous
increase)	
Comorbidities recorded in the 3-years before surgery	
Alcohol abuse	Binary
Atrial fibrillation	Binary
Blood loss anemia	Binary
Cancer	Binary
Cardiac valvular disease	Binary
Cerebrovascular disease	Binary
Chronic kidney disease	Binary
Chronic obstructive pulmonary disease	Binary
Coagulopathy	Binary
Deficiency anemia	Binary
Dementia	Binary
Depression	Binary
Diabetes	Binary
Dialysis	Binary
Drug abuse	Binary
Frailty	Binary
Heart failure	Binary
Hemiparesis or hemiplegia	Binary
Hypertension	Binary
Liver disease	Binary
Metastatic cancer	Binary
Myocardial infarction	Binary
Obesity	Binary
Peptic ulcer disease	Binary
Previous diagnosis of peripheral artery disease	Binary
Psychosis	Binary

Pulmonary circulatory disease	Binary
Rheumatic disease	Binary
Venous thromboembolism	Binary
Weight loss	Binary
Healthcare resource use	
Emergency Department visit in last year	Binary
Hospitalization in last year	Binary
Resource utilization band	5-level categorical
Lower limb revascularization surgery	
Surgical urgency	4-level categorical
Procedure	
Infrainguinal bypass	
Using autogenous graft material	Binary
Using synthetic graft material	Binary
Using composite graft material	Binary
Repair of leg arteries below the inguinal ligament	
Using autograft (e.g., vein patch) material	Binary
Using synthetic (e.g., Dacron patch) material	Binary
Without using the above material (e.g., embolectomy)	Binary
Year of surgery	Restricted cubic spline with 3 knots

Predictor or Covariate	Adjusted-OR (95% CI)	p-value
Use of neuraxial instead of general anesthesia	0.68 (0.57 to 0.83)	< 0.001
Demographics and hospital surgical volume		
Female	0.81 (0.69 to 0.95)	0.009
Urban instead of rural residence	1.03 (0.83 to 1.29)	0.78
Long-term care facility resident	1.59 (1.11 to 2.28)	0.01
Income quintile		
1 – Lowest	1.20 (0.95 to 1.51)	0.12
2	0.97 (0.76 to 1.23)	0.79
3	0.91 (0.70 to 1.16)	0.44
4	1.01 (0.79 to 1.29)	0.97
5 – Highest	Reference (1.00)	NA
Smoking cessation consultation in the year before surgery	0.86 (0.43 to 1.71)	0.67
Hospital-patient One-Year Mortality Risk score (per-point increase)	1.06 (1.04 to 1.08)	< 0.001
Comorbidities recorded in the 3-years before surgery	· · · · · · · · · · · · · · · · · · ·	•
Alcohol abuse	1.11 (0.73 to 1.68)	0.62
Atrial fibrillation	0.97 (0.78 to 1.21)	0.81
Blood loss anemia	1.98 (1.64 to 2.39)	< 0.001
Cancer	1.04 (0.78 to 1.39)	0.78
Cardiac valvular disease	1.05 (0.81 to 1.36)	0.69
Cerebrovascular disease	1.25 (0.95 to 1.63)	0.11
Chronic kidney disease	0.86 (0.65 to 1.63)	0.28
Chronic obstructive pulmonary disease	0.95 (0.81 to 1.11)	0.49
Coagulopathy	1.90 (1.48 to 2.45)	< 0.001
Deficiency anemia	0.49 (0.23 to 1.01)	0.05
Dementia	1.95 (1.34 to 2.83)	< 0.001
Depression	0.57 (0.36 to 0.90)	0.02
Diabetes	0.91 (0.78 to 1.07)	0.26
Dialysis	2.45 (1.79 to 3.36)	< 0.001
Drug abuse	1.70 (0.73 to 3.95)	0.22
Frailty	0.62 (0.51 to 0.75)	< 0.001
Heart failure	1.90 (1.59 to 2.26)	< 0.001
Hemiparesis or hemiplegia	0.89 (0.42 to 1.88)	0.77
Hypertension	0.89 (0.71 to 1.11)	0.31
Liver disease	1.15 (0.68 to 1.97)	0.60
Metastatic cancer	1.66 (0.94 to 2.92)	0.08
Myocardial infarction	1.01 (0.82 to 1.23)	0.95
Obesity	1.51 (0.99 to 2.29)	0.05
Peptic ulcer disease	1.13 (0.73 to 1.77)	0.58
Previous diagnosis of peripheral artery disease	0.76 (0.64 to 0.91)	0.002
Psychosis	1.27 (0.59 to 2.76)	0.54
Pulmonary circulatory disease	1.79 (1.27 to 2.53)	< 0.001
Rheumatic disease	0.76 (0.40 to 1.47)	0.42
Venous thromboembolism	1.19 (0.72 to 1.97)	0.51
Weight loss	1.70 (1.12 to 2.58)	0.01
Healthcare resource use	· · · · · · · · · · · · · · · · · · ·	•
Emergency Department visit in last year	0.88 (0.73 to 1.06)	0.17
Hospitalization in last year	0.74 (0.61 to 0.89)	0.002
Resource utilization band		
1 – Healthy user	$0.017 (1.04^{-25} \text{ to } 2.65^{21})$	0.88
2 – Low morbidity	0.32 (0.043 to 2.42)	0.27
3 – Moderate	0.27 (0.17 to 0.44)	< 0.001

eTable 3. Mixed-Effects Regression Model Examining the Adjusted Association Between Anesthetic Type and 30-Day Mortality Among the 20,988 Study Patients.

4 – High	0.55 (0.44 to 0.70)	< 0.001
5 – Very high	Reference (1.00)	NA
Lower limb revascularization surgery		
Urgency		
Elective	0.22 (0.11 to 0.45)	< 0.001
Urgent	0.55 (0.28 to 1.07)	0.08
Emergent	0.28 (0.03 to 2.24)	0.23
Critical	Reference (1.00)	NA
Procedure		
Infrainguinal bypass		
Using autogenous graft material	0.22 (0.12 to 0.43)	< 0.001
Using synthetic graft material	0.73 (0.41 to 1.29)	0.28
Using composite graft material	0.78 (0.23 to 2.64)	0.69
Repair of leg arteries below the inguinal ligament		
Using autograft (e.g., vein patch) material	0.51 (0.13 to 2.00)	0.34
Using synthetic (e.g., Dacron patch) material	0.34 (0.04 to 2.82)	0.32
Without using the above material (e.g., embolectomy)	0.64 (0.35 to 1.18)	0.15
Spline and Interaction Terms	Beta Coefficient (95%	p-value
	CI)*	
Spline terms		
Age (linear segment)	-0.036 (-0.057 to -0.015)	0.001
Age (spline segment 1)	0.19 (0.090 to 0.28)	< 0.001
Age 2 (spline segment 2)	-0.82 (-1.44 to -0.21)	0.009
Age 3 (spline segment 3)	1.08 (-0.13 to 2.29)	0.08
Hospital lower limb revascularization surgery volume (linear segment)	0.00051 (0.00051 to	< 0.001
	0.00051)	
Hospital lower limb revascularization surgery volume (spline segment	-0.0023 (-0.0023 to -	< 0.001
1)	0.0023)	
Hospital lower limb revascularization surgery volume (spline segment	0.0050 (0.0050 to 0.0050)	< 0.001
2)		
Hospital lower limb revascularization surgery volume (spline segment	-0.0032 (-0.0032 to -	0.75
3)	0.0032)	0.02
Year of surgery (linear segment)	-0.0047 (-0.093 to 0.083)	0.92
Year of surgery (spline segment 1)	-0.032 (-0.13 to 0.066)	0.52
Interaction terms		
Infrainguinal bypass	1.00 (0.00 + 1.00)	0.01
Elective*using autogenous graft material	1.08 (0.23 to 1.93)	0.01
Urgent*using autogenous graft material	0.73 (-0.084 to 1.54)	0.08
Emergent*using autogenous graft material	1.67 (-0.58 to 3.91)	0.15
Critical*using autogenous graft material	Reference (0)	NA
Elective*using synthetic graft material	0.083 (-0.71 to 0.87)	0.84
Urgent*using synthetic graft material	0.10 (-0.64 to 0.85)	0.79
Emergent*using synthetic graft material	1.16 (-1.06 to 3.38)	0.31
Critical*using synthetic graft material	Reference (0)	NA
Elective*using composite graft material	0.12 (-1.40 to 1.64)	0.88
Urgent*using composite graft material	-0.71 (-2.22 to 0.81)	0.36
Emergent*using composite graft material	0.74 (-2.40 to 3.87)	0.64
Critical*using composite graft material	Reference (0)	NA
Repair of leg arteries below the inguinal ligament		0.01
Elective*using autograft material	0.12 (-0.99 to 1.23)	0.84
Urgent*using autograft material	0.51 (-0.46 to 1.47)	0.30
Emergent*using autograft material	1.59 (-1.19 to 4.38)	0.26
Critical*using autograft material	Reterence (0)	NA
Elective*using synthetic material	1.28 (-1.12 to 3.67)	0.30

Urgent*using synthetic material	1.15 (-1.23 to 3.53)	0.34
Emergent*using synthetic material	3.17 (-0.71 to 7.05)	0.11
Critical*using synthetic material	Reference (0)	NA
Elective*without using the above material	0.71 (-0.17 to 1.58)	0.11
Urgent*without using the above material	0.32 (-0.59 to 1.13)	0.44
Emergent*without using the above material	0.67 (-1.79 to 3.13)	0.59
Critical*without using the above material	Reference (0)	NA

Where CI indicates confidence interval; NA, not applicable; and OR, odds ratio.

*Beta coefficients instead of ORs were provided for spline and interaction terms as they cannot be directly interpreted on their own.

eTable 4. Characteristics of the Propensity Score-Matched Cohorts.

Characteristic	No. (%) of Propensity		Absolute
	Score-Matched Patients		Standardized
	Receiving Anesthesia		Difference ^a
	Neuraxial	General	
	(n=6,453)	(n=14,535)	
Demographics			
Age, mean (SD), years	70.0 (11.0)	70.0 (11.0)	0
Female	2,104 (32.6)	4,840 (33.3)	0.01
Rural residence	1,123 (17.4)	2,486 (17.1)	0.01
Long-term care facility resident	123 (1.9)	320 (2.2)	0.02
Income quintile			
1 – Lowest	1,536 (23.8)	3,605 (24.8)	0.02
2	1,433 (22.2)	3,067 (21.1)	0.03
3	1,233 (19.1)	2,791 (19.2)	0
4	1,181 (18.3)	2,689 (18.5)	0
5 – Highest	1,071 (16.6)	2,398 (16.5)	0
Smoking cessation consultation in the year before surgery	174 (2.7)	378 (2.6)	0.01
Hospital-patient One-Year Mortality Risk score, mean (SD)	32.0 (6.0)	31.0 (6.0)	0
Comorbidities recorded in the 3-years before surgery			
Alcohol abuse	174 (2.7)	392 (2.7)	0
Atrial fibrillation	574 (8.9)	1,265 (8.7)	0.01
Blood loss anemia	736 (11.4)	1,686 (11.6)	0.01
Cancer	387 (6.0)	799 (5.5)	0.02
Cardiac valvular disease	226 (3.5)	523 (3.6)	0.01
Cerebrovascular disease	432 (6.7)	930 (6.4)	0.01
Chronic kidney disease	555 (8.6)	1,206 (8.3)	0.01
Chronic obstructive pulmonary disease	2,575 (39.9)	5,770 (39.7)	0
Coagulopathy	213 (3.3)	509 (3.5)	0.01
Deficiency anemia	58 (0.9)	145 (1.0)	0.01
Dementia	129 (2.0)	276 (1.9)	0.01
Depression	174 (2.7)	436 (3.0)	0.02
Diabetes	3,123 (48.4)	6,788 (46.7)	0.03
Dialysis	303 (4.7)	698 (4.8)	0
Drug abuse	26 (0.4)	58 (0.4)	0
Frailty	1,342 (20.8)	3,009 (20.7)	0
Heart failure	1,536 (23.8)	3,256 (22.4)	0.03
Hemiparesis or hemiplegia	52 (0.8)	116 (0.8)	0
Hypertension	5,201 (80.6)	11,599 (79.8)	0.02
Liver disease	71 (1.1)	189 (1.3)	0.02
Metastatic cancer	52 (0.8)	116 (0.8)	0
Myocardial infarction	871 (13.5)	1,919 (13.2)	0.01
Obesity	136 (2.1)	305 (2.1)	0
Peptic ulcer disease	136 (2.1)	291 (2.0)	0.01
Previous diagnosis of peripheral artery disease	2,484 (38.5)	5,741 (39.5)	0.02
Psychosis	19 (0.3)	58 (0.4)	0.02
Pulmonary circulatory disease	90 (1.4)	218 (1.5)	0.01
Rheumatic disease	71 (1.1)	174 (1.2)	0.01
Venous thromboembolism	77 (1.2)	174 (1.2)	0
Weight loss	103 (1.6)	261 (1.8)	0.02
Healthcare resource use			
Emergency Department visit in last year	4,027 (62.4)	9,070 (62.4)	0
Hospitalization in last year	2,626 (40.7)	5,930 (40.8)	0

Resource utilization band			
1, 2, or 3 – Healthy user or low or moderate morbidity	820 (12.7)	1,759 (12.1)	0.02
4 – High	1,484 (23.0)	3,358 (23.1)	0
5 – Very high	4,136 (64.1)	9,433 (64.9)	0.02
Lower limb revascularization surgery			
Hospital lower limb revascularization volume, mean (SD)	1440 (771)	1440 (772)	0
Urgency			
Elective	4,227 (65.5)	8,881 (61.1)	0.09
Urgent	1,820 (28.2)	4,172 (28.7)	0.01
Emergent	110 (1.7)	320 (2.2)	0.04
Critical	419 (6.5)	1,163 (8.0)	0.06
Procedure			
Infrainguinal bypass	5,510 (85.4)	12,297 (84.6)	0.02
Using autogenous graft material	3,297 (51.1)	7,704 (53.0)	0.04
Using synthetic graft material	2,065 (32.0)	4,288 (29.5)	0.05
Using composite graft material	148 (2.3)	305 (2.1)	0.02
Repair of leg arteries below the inguinal ligament	729 (11.3)	1,788 (12.3)	0.03
Using autograft (e.g., vein patch) material	232 (3.6)	610 (4.2)	0.03
Using synthetic (e.g., Dacron patch) material	181 (2.8)	480 (3.3)	0.03
Without using the above material (e.g., embolectomy)	316 (4.9)	698 (4.8)	0

Where NA indicates not applicable and SD, standard deviation.

^aThe standardized difference allows comparison of the difference in prevalence of binary covariates, or the average of continuous covariates, between treatment groups without the influence of sample size; values >0.1 indicate substantive differences.

^bPrivacy legislation does not allow reporting of cell sizes ≤ 6 or cells that allow calculation of a cell ≤ 6 .

Characteristic	No. (%) of Patients		Absolute
	Receiving Anesthesia		Standardized
			Difference ^a
	Neuraxial	General	
	(n=4,449)	(n=8,727)	
Demographics	• · · · ·		
Age, mean (SD), years	76.3 (6.7)	75.7 (6.5)	0.09
Female	1,574 (35.4)	3,160 (36.2)	0.02
Rural residence	740 (16.6)	1,420 (16.3)	0.01
Long-term care facility resident	143 (3.2)	206 (2.4)	0.05
Income quintile			
1 – Lowest	962 (21.7)	1,900 (21.8)	0.00
2	977 (22.0)	1,910 (21.9)	0.00
3	871 (19.6)	1,676 (19.2)	0.01
4	845 (19.0)	1,616 (18.6)	0.01
5 – Highest	782 (17.6)	1,607 (18.5)	0.02
Smoking cessation consultation in the year before surgery	75 (1.7)	136 (1.6)	0.01
Hospital-patient One-Year Mortality Risk score, mean (SD)	33.5 (5.5)	33.4 (5.8)	0.02
Comorbidities recorded in the 3-years before surgery			
Alcohol abuse	105 (2.4)	200 (2.3)	0.00
Atrial fibrillation	478 (10.7)	1,003 (11.5)	0.01
Blood loss anemia	572 (12.9)	1,126 (12.9)	0.03
Cancer	288 (6.5)	608 (7.0)	0.00
Cardiac valvular disease	181 (4.1)	675 (7.7)	0.02
Cerebrovascular disease	324 (7.3)	638 (7.3)	0.15
Chronic kidney disease	431 (9.7)	687 (7.9)	0.00
Chronic obstructive pulmonary disease	1.921 (43.2)	3.497 (40.1)	0.06
Coagulopathy	146 (3.3)	408 (4.7)	0.06
Deficiency anemia	49 (1.1)	98 (1.1)	0.07
Dementia	120 (2.7)	205 (2.4)	0.00
Depression	115 (2.6)	200 (2.3)	0.02
Diabetes	2.165 (48.7)	4.014 (46.0)	0.02
Dialysis	209 (4.7)	315 (3.6)	0.05
Drug abuse	11 (0.3)	19 (0.2)	0.06
Frailty	1.097 (24.7)	2.007 (23.0)	0.02
Heart failure	1.255 (28.2)	2.300 (26.4)	0.04
Hemiparesis or hemiplegia	34 (0.8)	73 (0.8)	0.04
Hypertension	3.832 (86.1)	7.633 (87.5)	0.00
Liver disease	46 (1.0)	77 (0.9)	0.04
Metastatic cancer	31 (0.7)	79 (0.9)	0.01
Myocardial infarction	602 (13.5)	1.221 (14.0)	0.02
Obesity	61 (1.4)	141 (1.6)	0.01
Peptic ulcer disease	105 (2.4)	179 (2.1)	0.02
Previous diagnosis of peripheral artery disease	1,796 (40.4)	2,936 (33.6)	0.02
Psychosis	17 (0.4)	46 (0.5)	0.14
Pulmonary circulatory disease	71 (1.6)	180 (2.1)	0.01
Rheumatic disease	51 (1.2)	113 (1.3)	0.04
Venous thromboembolism	42 (0.9)	104 (1.2)	0.01
Weight loss	85 (1.9)	152 (1.7)	0.03
Outpatient prescription drugs received in the 6-months before surgery			
Total no. of unique drugs, median (IQR)	7 (5-10)	7 (4-10)	0.01

eTable 5. Characteristics of the 13,176 Study Patients \geq 65 Years Old With Outpatient Prescription Drug Data Stratified By Anesthetic Technique.

Anticoagulant	749 (16.8)	1,612 (18.5)	0.04
Antiplatelet	590 (13.3)	1,513 (17.3)	0.11
Antipsychotic	108 (2.4)	204 (2.3)	0.01
Benzodiazepine	934 (21.0)	1,653 (18.9)	0.05
Insulin	653 (14.7)	1,129 (12.9)	0.05
Opioid	2,188 (49.2)	4,123 (47.2)	0.04
Oral corticosteroid	353 (7.9)	713 (8.2)	0.01
Oral diabetes medication	1,248 (28.1)	2,261 (25.9)	0.05
Healthcare resource use	•		
Emergency Department visit in last year	2,830 (63.6)	5,455 (62.5)	0.02
Hospitalization in last year	1,861 (41.8)	3,724 (42.7)	0.02
Resource utilization band			
1 – Healthy user	_b	_ b	N/A
2 – Low morbidity	- ^b	_ b	N/A
3 – Moderate	490 (11.0)	780 (8.9)	0.07
4 – High	985 (22.1)	1,948 (22.3)	0.00
5 – Very high	2,974 (66.9)	5,998 (68.7)	0.04
Lower limb revascularization surgery			
Hospital lower limb revascularization volume, mean (SD)	1,395 (784)	1,469 (846)	0.09
Urgency			
Elective	2,749 (61.8)	5,146 (59.0)	0.06
Urgent	1,375 (30.9)	2,523 (28.9)	0.04
Emergent	74 (1.7)	182 (2.1)	0.03
Critical	251 (5.6)	876 (10.0)	0.16
Procedure			
Infrainguinal bypass	3,841 (86.3)	6,637 (76.1)	0.26
Using autogenous graft material	2,319 (52.1)	3,761 (43.1)	0.18
Using synthetic graft material	1,420 (31.9)	2,635 (30.2)	0.04
Using composite graft material	102 (2.3)	241 (2.8)	0.03
Repair of leg arteries below the inguinal ligament	448 (10.1)	1,800 (20.6)	0.29
Using autograft (e.g., vein patch) material	154 (3.5)	912 (10.5)	0.28
Using synthetic (e.g., Dacron patch) material	109 (2.5)	328 (3.8)	0.07
Without using the above material (e.g.,	185 (4.2)	560 (6.4)	0.10
thromboembolectomy)			

Where NA indicates not applicable; IQR, interquartile range; no., number; and SD, standard deviation.

^aThe standardized difference allows comparison of the difference in prevalence of binary covariates, or the average of continuous covariates, between treatment groups without the influence of sample size; values >0.1 indicate substantive differences.

^bPrivacy legislation does not allow reporting of cell sizes ≤ 6 or cells that allow calculation of a cell ≤ 6 .

Predictor or Covariata	Adjusted OP (05% CI)	n voluo
Use of neurovial instead of general anesthesia	0.74 (0.60 to 0.90)	
Demographics and hospital surgical volume	0.74 (0.00 to 0.90)	0.003
Energia Energia Energia Surgical Volume	$0.77 (0.64 \pm 0.02)$	0.004
I reliate	0.77(0.04 to 0.92)	0.004
Long term core facility resident	0.93(0.73 to 1.19)	0.30
	1.00 (1.14 to 2.43)	0.009
	1.06 (0.82 to 1.26)	0.69
1 - Lowest	$\frac{1.06(0.82101.36)}{0.01(0.70+1.18)}$	0.08
	0.91(0.70101.18)	0.47
3		0.17
4	0.91 (0.70 to 1.19)	0.50
5 – Hignest	Reference (1.00)	0.70
Smoking cessation consultation in the year before surgery	0.88 (0.35 to 2.22)	0.79
Hospital-patient One-Year Mortality Risk score (per-point increase)	1.05 (1.03 to 1.07)	<0.001
Comorbidities recorded in the 3-years before surgery	1.12 (0.60 - 1.07)	
Alcohol abuse	1.13 (0.69 to 1.87)	0.62
Atrial fibrillation	0.96 (0.74 to 1.24)	0.76
Blood loss anemia	1.98 (1.60 to 2.44)	<0.001
Cancer	0.99 (0.72 to 1.36)	0.93
Cardiac valvular disease	1.03 (0.77 to 1.38)	0.83
Cerebrovascular disease	1.10 (0.82 to 1.48)	0.54
Chronic kidney disease	0.90 (0.66 to 1.22)	0.49
Chronic obstructive pulmonary disease	0.94 (0.79 to 1.12)	0.47
Coagulopathy	1.52 (1.12 to 2.06)	0.007
Deficiency anemia	0.57 (0.27 to 1.18)	0.13
Dementia	2.10 (1.43 to 3.08)	< 0.001
Depression	0.71 (0.41 to 1.21)	0.21
Diabetes	0.91 (0.73 to 1.15)	0.45
Dialysis	2.38 (1.66 to 3.43)	< 0.001
Drug abuse	3.12 (1.14 to 8.54)	0.03
Frailty	0.63 (0.51 to 0.77)	< 0.001
Heart failure	1.81 (1.49 to 2.20)	< 0.001
Hemiparesis or hemiplegia	0.88 (0.38 to 2.05)	0.76
Hypertension	0.79 (0.61 to 1.04)	0.09
Liver disease	1.45 (0.76 to 2.76)	0.26
Metastatic cancer	1.38 (0.68 to 2.81)	0.37
Myocardial infarction	1.03 (0.83 to 1.29)	0.78
Obesity	1.51 (0.87 to 2.62)	0.15
Peptic ulcer disease	1.23 (0.76 to 1.99)	0.39
Previous diagnosis of peripheral artery disease	0.80 (0.66 to 0.97)	0.03
Psychosis	1.26 (0.49 to 3.21)	0.63
Pulmonary circulatory disease	1.67(1.10 to 2.54)	0.02
Rheumatic disease	0.86 (0.43 to 1.70)	0.66
Venous thromboembolism	1.36(0.75 to 2.46)	0.30
Weight loss	1.49 (0.94 to 2.37)	0.09
Outpatient prescription drugs received in the 6-months before surgery		0.07
Anticoagulant	0.96 (0.77 to 1.21)	0.73
Antinlatelet	1.16(0.92 to 1.47)	0.75
Antipsychotic	0.79 (0.47 to 1.32)	0.20
Benzodiazenine	0.88(0.71 to 1.02)	0.30
Insulin	0.86(0.65 to 1.14)	0.24
Opioid	$0.81 (0.67 \pm 0.07)$	0.30
	0.01(0.0710(0.77))	0.02

eTable 6. Mixed-Effects Regression Model Examining the Adjusted Association Between Anesthetic Type and 30-Day Mortality Among the 13,176 Patients \geq 65 Years-Old With Outpatient Prescription Drug Data.

Oral corticosteroid	1.26 (0.96 to 1.66)	0.09
Oral diabetes medication	0.96 (0.75 to 1.24)	0.76
Healthcare resource use		
Emergency Department visit in last year	0.95 (0.77 to 1.18)	0.66
Hospitalization in last year	0.70 (0.56 to 0.86)	< 0.001
Resource utilization band		
2 – Low morbidity	$0.019 (0 \text{ to } 2.82^{22})$	0.89
3 – Moderate	0.23 (0.12 to 0.42)	< 0.001
4 - High	0.53 (0.41 to 0.69)	< 0.001
5 – Very high	Reference (1.00)	NA
Lower limb revascularization surgery		
Urgency		
Elective	0.74 (0.60 to 0.90)	0.003
Urgent	0.20 (0.091 to 0.46)	< 0.001
Emergent	0.46 (0.21 to 1.02)	0.05
Critical	Reference (1.00)	NA
Procedure		
Infrainguinal bypass		
Using autogenous graft material	0.25 (0.12 to 0.53)	< 0.001
Using synthetic graft material	0.23 (0.12 to 0.03)	0.33
Using composite graft material	1.06(0.17 to 2.89)	0.63
Repair of leg arteries below the inquinal ligament	1.00 (0.17 to 2.03)	0.05
Using autograft (e.g. vein patch) material	0.0038 (0.00000029 to	0.36
Using utograft (0.5., Von paten) indertai	511 78)	0.50
Using synthetic (e.g., Dacron patch) material	0.0064 (0.000000033 to	0.49
	12570.40)	0112
Without using the above material (e.g., embolectomy)	0.54 (0.19 to 1.48)	0.23
		0.45
Spline and Interaction Terms	Beta Coefficient (95%	p-value
Spline and Interaction Terms	Beta Coefficient (95% CI)*	p-value
Spline terms	Beta Coefficient (95% CI)*	p-value
Spline and Interaction Terms Spline terms Age (linear segment)	Beta Coefficient (95% CI)* 0.17 (0.033 to 0.31)	p-value
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1)	Beta Coefficient (95% CI)* 0.17 (0.033 to 0.31) -0.75 (-1.64 to 0.13)	0.23 p-value 0.01 0.09
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2)	0.17 (0.033 to 0.31) 0.17 (0.033 to 0.31) -0.75 (-1.64 to 0.13) 1.96 (-0.83 to 4.74)	0.01 0.09 0.17
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3)	0.17 (0.17 to 1.10) Beta Coefficient (95% CI)* 0.17 (0.033 to 0.31) -0.75 (-1.64 to 0.13) 1.96 (-0.83 to 4.74) -1.35 (-4.17 to 1.48)	0.01 0.09 0.17 0.35
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment)	0.17 (0.17 to 1.10) Beta Coefficient (95% CI)* 0.17 (0.033 to 0.31) -0.75 (-1.64 to 0.13) 1.96 (-0.83 to 4.74) -1.35 (-4.17 to 1.48) -0.059 (-0.19 to 0.070)	0.01 0.09 0.17 0.35 0.37
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1)	0.17 (0.17 to 1.16) Beta Coefficient (95% CI)* 0.17 (0.033 to 0.31) -0.75 (-1.64 to 0.13) 1.96 (-0.83 to 4.74) -1.35 (-4.17 to 1.48) -0.059 (-0.19 to 0.070) 0.31 (-0.45 to 1.07)	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2)	Beta Coefficient (95% CI)* 0.17 (0.033 to 0.31) -0.75 (-1.64 to 0.13) 1.96 (-0.83 to 4.74) -1.35 (-4.17 to 1.48) -0.059 (-0.19 to 0.070) 0.31 (-0.45 to 1.07) -0.73 (-4.72 to 3.27)	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3)	Beta Coefficient (95% CI)* 0.17 (0.033 to 0.31) -0.75 (-1.64 to 0.13) 1.96 (-0.83 to 4.74) -1.35 (-4.17 to 1.48) -0.059 (-0.19 to 0.070) 0.31 (-0.45 to 1.07) -0.73 (-4.72 to 3.27) -0.028 (-4.91 to 4.85)	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment 1) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment)	Beta Coefficient (95% CI)* 0.17 (0.033 to 0.31) -0.75 (-1.64 to 0.13) 1.96 (-0.83 to 4.74) -1.35 (-4.17 to 1.48) -0.059 (-0.19 to 0.070) 0.31 (-0.45 to 1.07) -0.73 (-4.72 to 3.27) -0.028 (-4.91 to 4.85) 0.00047 (0.00047 to	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment)	Beta Coefficient (95% CI)* 0.17 (0.033 to 0.31) -0.75 (-1.64 to 0.13) 1.96 (-0.83 to 4.74) -1.35 (-4.17 to 1.48) -0.059 (-0.19 to 0.070) 0.31 (-0.45 to 1.07) -0.73 (-4.72 to 3.27) -0.028 (-4.91 to 4.85) 0.00047 (0.00047 to 0.00047)	0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment)	Beta Coefficient (95% CI)* 0.17 (0.033 to 0.31) -0.75 (-1.64 to 0.13) 1.96 (-0.83 to 4.74) -1.35 (-4.17 to 1.48) -0.059 (-0.19 to 0.070) 0.31 (-0.45 to 1.07) -0.73 (-4.72 to 3.27) -0.028 (-4.91 to 4.85) 0.00047 (0.00047 to 0.00047) -0.0022 (-0.0022 to -0.0022)	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001 <0.001
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment 1) Hospital lower limb revascularization surgery volume (spline segment 1)	Beta Coefficient (95% CI)* 0.17 (0.033 to 0.31) -0.75 (-1.64 to 0.13) 1.96 (-0.83 to 4.74) -1.35 (-4.17 to 1.48) -0.059 (-0.19 to 0.070) 0.31 (-0.45 to 1.07) -0.73 (-4.72 to 3.27) -0.028 (-4.91 to 4.85) 0.00047 (0.00047 to 0.00047) -0.0022 (-0.0022 to -0.0022)	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment) Hospital lower limb revascularization surgery volume (spline segment 1) Hospital lower limb revascularization surgery volume (spline segment 1)	$\begin{array}{c} \textbf{Beta Coefficient (95\% CI)*} \\ \hline \textbf{Beta Coefficient (95\% CI)*} \\ \hline 0.17 (0.033 to 0.31) \\ -0.75 (-1.64 to 0.13) \\ 1.96 (-0.83 to 4.74) \\ -1.35 (-4.17 to 1.48) \\ -0.059 (-0.19 to 0.070) \\ \hline 0.31 (-0.45 to 1.07) \\ -0.73 (-4.72 to 3.27) \\ -0.028 (-4.91 to 4.85) \\ \hline 0.00047 (0.00047 to \\ 0.00047) \\ -0.0022 (-0.0022 to -0.0022) \\ \hline 0.0047 (0.0047 to 0.0047) \end{array}$	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001 <0.001 <0.001
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment) Hospital lower limb revascularization surgery volume (spline segment 1) Hospital lower limb revascularization surgery volume (spline segment 2) You hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 2)	Beta Coefficient (95% CI)* 0.17 (0.033 to 0.31) -0.75 (-1.64 to 0.13) 1.96 (-0.83 to 4.74) -1.35 (-4.17 to 1.48) -0.059 (-0.19 to 0.070) 0.31 (-0.45 to 1.07) -0.73 (-4.72 to 3.27) -0.028 (-4.91 to 4.85) 0.00047 (0.00047 to 0.0022) 0.0047 (0.0047 to 0.0047)	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 2)	Beta Coefficient (95% CI)* Beta Coefficient (95% CI)* $0.17 (0.033 to 0.31)$ $-0.75 (-1.64 to 0.13)$ $1.96 (-0.83 to 4.74)$ $-1.35 (-4.17 to 1.48)$ $-0.059 (-0.19 to 0.070)$ $0.31 (-0.45 to 1.07)$ $-0.73 (-4.72 to 3.27)$ $-0.028 (-4.91 to 4.85)$ $0.00047 (0.00047 to 0.0022)$ $0.0047 (0.0047 to 0.0047)$ $-0.0026 (-0.024 to 0.019)$	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001 <0.001 <0.001 0.81
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment 1) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 3) Hospital lower limb revascularization surgery volume (spline segment 3)	Beta Coefficient (95% CI)* Beta Coefficient (95% CI)* $0.17 (0.033 \text{ to } 0.31)$ $-0.75 (-1.64 \text{ to } 0.13)$ $1.96 (-0.83 \text{ to } 4.74)$ $-1.35 (-4.17 \text{ to } 1.48)$ $-0.059 (-0.19 \text{ to } 0.070)$ $0.31 (-0.45 \text{ to } 1.07)$ $-0.73 (-4.72 \text{ to } 3.27)$ $-0.028 (-4.91 \text{ to } 4.85)$ $0.00047 (0.00047 \text{ to } 0.0022)$ $0.0047 (0.0047 \text{ to } 0.0047)$ $-0.0026 (-0.024 \text{ to } 0.019)$	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 1) Hospital lower limb revascularization surgery volume (spline segment 1) Hospital lower limb revascularization surgery volume (spline segment 3) Year of surgery (linear segment)	$\begin{array}{c} \textbf{Beta Coefficient (95\% CI)*} \\ \hline \textbf{Beta Coefficient (95\% CI)*} \\ \hline 0.17 (0.033 to 0.31) \\ -0.75 (-1.64 to 0.13) \\ 1.96 (-0.83 to 4.74) \\ -1.35 (-4.17 to 1.48) \\ -0.059 (-0.19 to 0.070) \\ 0.31 (-0.45 to 1.07) \\ -0.73 (-4.72 to 3.27) \\ -0.028 (-4.91 to 4.85) \\ 0.00047 (0.00047 to \\ 0.00047) \\ -0.0022 (-0.0022 to -0.0022) \\ \hline 0.0047 (0.0047 to 0.0047) \\ -0.0026 (-0.024 to 0.019) \\ -0.021 (-0.12 to 0.080) \\ \end{array}$	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001 <0.001 0.81 0.68
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment 1) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 1) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 3) Year of surgery (linear segment) Year of surgery (spline segment 1)	$\begin{array}{c} \textbf{Beta Coefficient (95\% CI)*} \\ \hline \textbf{Beta Coefficient (95\% CI)*} \\ \hline 0.17 (0.033 to 0.31) \\ -0.75 (-1.64 to 0.13) \\ 1.96 (-0.83 to 4.74) \\ -1.35 (-4.17 to 1.48) \\ -0.059 (-0.19 to 0.070) \\ 0.31 (-0.45 to 1.07) \\ -0.73 (-4.72 to 3.27) \\ -0.028 (-4.91 to 4.85) \\ 0.00047 (0.00047 to \\ 0.00047) \\ -0.0022 (-0.0022 to -0.0022) \\ \hline 0.0047 (0.0047 to 0.0047) \\ -0.0026 (-0.024 to 0.019) \\ -0.021 (-0.12 to 0.080) \\ -0.018 (-0.13 to 0.095) \\ \hline \end{array}$	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001 <0.001 <0.001 0.81 0.68 0.75
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 1) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 3) Year of surgery (linear segment) Year of surgery (spline segment 1) Interaction terms	Beta Coefficient (95% CI)* Beta Coefficient (95% CI)* $0.17 (0.033 \text{ to } 0.31)$ $-0.75 (-1.64 \text{ to } 0.13)$ $1.96 (-0.83 \text{ to } 4.74)$ $-1.35 (-4.17 \text{ to } 1.48)$ $-0.059 (-0.19 \text{ to } 0.070)$ $0.31 (-0.45 \text{ to } 1.07)$ $-0.73 (-4.72 \text{ to } 3.27)$ $-0.028 (-4.91 \text{ to } 4.85)$ $0.00047 (0.00047 \text{ to } 0.0022)$ $0.0047 (0.0047 \text{ to } 0.0047)$ $-0.022 (-0.022 \text{ to } -0.0022)$ $0.0047 (0.0047 \text{ to } 0.0047)$ $-0.021 (-0.12 \text{ to } 0.080)$ $-0.018 (-0.13 \text{ to } 0.095)$	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment) Hospital lower limb revascularization surgery volume (spline segment 1) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 1) Hospital lower limb revascularization surgery volume (spline segment 3) Year of surgery (linear segment) Year of surgery (spline segment 1) Interaction terms Infrainguinal bypass	$\begin{array}{c} \textbf{Beta Coefficient (95\% CI)^{*}} \\ \hline \textbf{Beta Coefficient (95\% CI)^{*}} \\ \hline \textbf{0.17 (0.033 to 0.31)} \\ -0.75 (-1.64 to 0.13) \\ 1.96 (-0.83 to 4.74) \\ -1.35 (-4.17 to 1.48) \\ -0.059 (-0.19 to 0.070) \\ \hline \textbf{0.31 (-0.45 to 1.07)} \\ -0.73 (-4.72 to 3.27) \\ -0.028 (-4.91 to 4.85) \\ \hline \textbf{0.00047 (0.00047 to 0.00047 to 0.00047)} \\ -0.0022 (-0.0022 to -0.0022) \\ \hline \textbf{0.0047 (0.0047 to 0.0047)} \\ -0.0026 (-0.024 to 0.019) \\ -0.021 (-0.12 to 0.080) \\ -0.018 (-0.13 to 0.095) \\ \hline \end{array}$	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment) Hospital lower limb revascularization surgery volume (spline segment 1) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 1) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 3) Year of surgery (linear segment) Year of surgery (spline segment 1) Interaction terms Infrainguinal bypass Elective*using autogenous graft material	Beta Coefficient (95% CI)* Beta Coefficient (95% CI)* $0.17 (0.033 \text{ to } 0.31)$ $-0.75 (-1.64 \text{ to } 0.13)$ $1.96 (-0.83 \text{ to } 4.74)$ $-1.35 (-4.17 \text{ to } 1.48)$ $-0.059 (-0.19 \text{ to } 0.070)$ $0.31 (-0.45 \text{ to } 1.07)$ $-0.73 (-4.72 \text{ to } 3.27)$ $-0.028 (-4.91 \text{ to } 4.85)$ $0.00047 (0.00047 \text{ to } 0.0022)$ $0.0047 (0.0047 \text{ to } 0.0022)$ $0.0047 (0.0047 \text{ to } 0.0047)$ $-0.021 (-0.12 \text{ to } 0.080)$ $-0.018 (-0.13 \text{ to } 0.095)$ $-0.018 (-0.12 \text{ to } 2.05)$	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment) Hospital lower limb revascularization surgery volume (spline segment 1) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 1) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 3) Year of surgery (linear segment) Year of surgery (spline segment 1) Interaction terms Infrainguinal bypass Elective*using autogenous graft material Urgent*using autogenous graft material	Beta Coefficient (95% CI)* Beta Coefficient (95% CI)* $0.17 (0.033 \text{ to } 0.31)$ $-0.75 (-1.64 \text{ to } 0.13)$ $1.96 (-0.83 \text{ to } 4.74)$ $-1.35 (-4.17 \text{ to } 1.48)$ $-0.059 (-0.19 \text{ to } 0.070)$ $0.31 (-0.45 \text{ to } 1.07)$ $-0.73 (-4.72 \text{ to } 3.27)$ $-0.028 (-4.91 \text{ to } 4.85)$ $0.00047 (0.00047 \text{ to } 0.0022)$ $0.0047 (0.0047 \text{ to } 0.0047)$ $-0.022 (-0.022 \text{ to } -0.0022)$ $0.0047 (0.0047 \text{ to } 0.0047)$ $-0.021 (-0.12 \text{ to } 0.080)$ $-0.018 (-0.13 \text{ to } 0.095)$	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001
Spline and Interaction Terms Spline terms Age (linear segment) Age (spline segment 1) Age 2 (spline segment 2) Age 3 (spline segment 3) Total no. of unique drugs (linear segment) Total no. of unique drugs (spline segment 1) Total no. of unique drugs (spline segment 2) Total no. of unique drugs (spline segment 3) Hospital lower limb revascularization surgery volume (linear segment) Hospital lower limb revascularization surgery volume (spline segment 1) Hospital lower limb revascularization surgery volume (spline segment 2) Hospital lower limb revascularization surgery volume (spline segment 1) Hospital lower limb revascularization surgery volume (spline segment 2) Year of surgery (linear segment) Year of surgery (spline segment 1) Interaction terms Infrainguinal bypass Elective*using autogenous graft material Urgent*using autogenous graft material	Beta Coefficient (95% CI)* Beta Coefficient (95% CI)* 0.17 (0.033 to 0.31) $-0.75 (-1.64 \text{ to } 0.13)$ 1.96 (-0.83 to 4.74) $-1.35 (-4.17 \text{ to } 1.48)$ -0.059 (-0.19 to 0.070) $0.31 (-0.45 \text{ to } 1.07)$ -0.73 (-4.72 to 3.27) $-0.028 (-4.91 \text{ to } 4.85)$ 0.00047 (0.00047 to 0.0047) $-0.0022 (-0.0022 \text{ to } -0.0022)$ 0.0047 (0.0047 to 0.0047) $-0.0026 (-0.024 \text{ to } 0.019)$ -0.021 (-0.12 to 0.080) $-0.018 (-0.13 \text{ to } 0.095)$ 1.09 (0.12 to 2.05) $0.82 (-0.12 \text{ to } 17.55)$	0.23 p-value 0.01 0.09 0.17 0.35 0.37 0.42 0.72 0.99 <0.001

Elective*using synthetic graft material	0.25 (-0.66 to 1.16)	0.59
Urgent*using synthetic graft material	0.28 (-0.60 to 1.16)	0.53
Emergent*using synthetic graft material	4.73 (-7.67 to 17.13)	0.45
Critical*using synthetic graft material	Reference (0)	NA
Elective*using composite graft material	-0.13 (-1.95 to 1.68)	0.89
Urgent*using composite graft material	-0.45 (-2.18 to 1.28)	0.61
Emergent*using composite graft material	4.24 (-8.38 to 16.85)	0.51
Critical*using composite graft material	Reference (0)	NA
Repair of leg arteries below the inguinal ligament		
Elective*using autograft material	6.24 (-5.60 to 18.07)	0.30
Urgent*using autograft material	5.32 (-6.52 to 17.16)	0.38
Emergent*using autograft material	10.88 (-6.36 to 28.13)	0.22
Critical*using autograft material	Reference (0)	NA
Elective*using synthetic material	5.50 (-9.04 to 20.03)	0.46
Urgent*using synthetic material	5.38 (-9.16 to 19.92)	0.47
Emergent*using synthetic material	10.47 (-8.75 to 29.68)	0.29
Critical*using synthetic material	Reference (0)	NA
Elective*without using the above material	0.29 (-1.17 to 1.76)	0.70
Urgent*without using the above material	1.04 (-0.22 to 2.30)	0.11
Emergent*without using the above material	5.53 (-7.09 to 18.14)	0.39
Critical*without using the above material	Reference (0)	NA

Where CI indicates confidence interval; NA, not applicable; and OR, odds ratio.

*Beta coefficients instead of ORs were provided for spline and interaction terms as they cannot be directly interpreted on their own.

Secondary Outcome	Incidence, No./Total (%)		Unadjusted OR	Unadjusted Absolute	p-value for	Adjusted OR	p-value for
	Neuraxial	General	(95% CI)	Difference (95% CI)	Unadjusted	(95% CI)	Adjusted
	Anesthesia	Anesthesia			Comparison		Comparison
In-hospital cardiac, pulmonary, or renal complications ^a	428 (6.6)	1261 (8.6)	0.74 (0.66 to 0.83)	-2.0% (-1.3% to 2.8%)	< 0.001	0.73 (0.63 to 0.85)	<0.001
Major adverse cardiac event ^b	255 (3.9)	720 (4.9)	0.80 (0.69 to 0.92)	-1.0% (-0.4% to -1.6%)	< 0.001	0.72 (0.60 to 0.87)	< 0.001
Pneumonia	77 (1.2)	234 (1.6)	0.74 (0.57 to 0.96)	-0.4% (-0.1% to -0.7%)	0.02	0.81 (0.60 to 1.11)	0.19
Venous thromboembolism	15 (0.2)	80 (0.5)	0.42 (0.24 to 0.73)	-0.3% (-0.2% to -0.5%)	0.001	_ ^c	_c
Acute kidney injury	41 (0.6)	191 (1.3)	0.48 (0.34 to 0.67)	-0.7% (-0.04% to -0.9%)	< 0.001	_c	_c
Cerebrovascular event ^d	6 (0.1)	35 (0.2)	0.38 (0.16 to 0.90)	-0.1% (-0.04% to -0.3%)	0.03		_c
Hospital readmissions	743 (11.4)	1669 (11.4)	1.00 (0.91 to 1.10)	0% (-1.0% to 0.9%)	0.98	0.59 (0.32 to 1.10)	0.11

eTable 7. Incidence of Secondary Outcomes and Results of Mixed-Effects Regression Models Examining Differences in These Outcomes Between Groups.

Where CI indicates confidence interval and OR, odds ratio.

^aWe decided *a priori* to analyze the adjusted odds of in-hospital cardiopulmonary and renal complications as a composite outcome to improve power.

^bIncludes acute coronary syndrome, heart failure, ventricular arrhythmia, or cardiac arrest.

^cNumber of events was too low to allow for fully-adjusted regression modeling.

^d*Post-hoc* analysis; includes transient ischemic attack and ischemic or hemorrhagic stroke.



eFigure 1. Loess smoothed plot of the percentage of neuraxial anesthesia, anticoagulant, and antiplatelet use across the study period. Shaded areas around the plotted line represent 95% confidence intervals.